Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial-Reference-Cited by-同舟云学术

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial

Published:2015-12 Issue:12 Volume:10 Page:1745-1753
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Paz-Ares Luis,Hirsh Vera,Zhang Li,de Marinis Filippo,Yang James Chih-Hsin,Wakelee Heather A.,Seto Takashi,Wu Yi-Long,Novello Silvia,Juhász Erszébet,Arén Osvaldo,Sun Yan,Schmelter Thomas,Ong Teng Jin,Peña Carol,Smit Egbert F.,Mok Tony S.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC);Langer;Cancer Treat Rev,2013

2. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004

3. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Sorafenib in the Management of Non-Small Cell Lung Cancer: A Systematic Review;Barw Medical Journal;2024-06-24

2. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma;International Immunopharmacology;2024-05

3. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments;Drugs;2024-04-16

4. Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer;Medical Sciences;2024-04-07

5. RSM-CCD optimized hollow mesoporous silica nanospheres encapsulating sorafenib induce mitochondrial membrane potential mediated apoptotic cell death in non-small cell lung cancer;Microporous and Mesoporous Materials;2024-04